No Data
GTJA (02611) spent 16.8435 million yuan to repurchase 1 million A shares on April 18.
GTJA (02611) announced that on April 18, 2025, it will invest 16.8435 million yuan (RMB...)
Guotai Junan gives a first-time 'Shareholding' rating to Ying'en Bio-B with a Target Price of HKD 300.70.
Guotai Junan released a Research Report stating that it has initiated coverage of CStone Pharmaceuticals-B (09606) with a "Shareholding" rating. The company focuses on the research and development of ADC new drugs, achieving multiple license-out authorizations, and laying out its presence in the Global market. Core products are entering the harvest period. Expected revenues from 2025 to 2027 are 1.6/1.976/2.207 billion yuan. Based on absolute and relative valuation methods, a Target Price of 300.70 Hong Kong dollars per share is given.
Guotai Junan International Proposes New Articles of Association
GTJA (02611.HK) spent 74.4724 million yuan to repurchase 4.4503 million A shares on April 16.
On April 16, Gelonghui reported that GTJA (02611.HK) announced the repurchase of 4.4503 million A shares at a cost of 74.4724 million yuan on April 16, with a repurchase price per share ranging from 16.62 to 16.78 yuan.
GTJA (02611.HK) spent 16.77 million HKD to buy back 1 million shares on April 15.
On April 15, GC Capital announced that GTJA (02611.HK) spent 16.77 million Hong Kong dollars to repurchase 1 million shares.
GTJA (02611.HK) will hold a Board of Directors meeting on April 29 to consider and approve the first quarter performance.
Gelonghui reported on April 15 that GTJA (02611.HK) announced that the Board of Directors meeting will be held on April 29, 2025 (Tuesday) to consider and approve the unaudited performance of the company and its subsidiaries for the first quarter ending March 31, 2025.
Jimmy w : Does this mean Futu will take off?
bullrider_21 OP Jimmy w : I think after a consolidation, it will rise again.